Domenico Ribatti
University of Bari
965 Papers
6.1K Citations
Domenico Ribatti is an academic researcher from University of Bari. The author has contributed to research in topics: Angiogenesis & Biology. The author has an hindex of 96, co-authored 913 publications. Previous affiliations of Domenico Ribatti include University of Genoa & National Institutes of Health.
Chat about Author
Papers
Chorioallantoic Membrane in the Study of Angiogenesis, Antiangiogenesis, and the Vascularization of Grafted Tissues
Domenico Ribatti
- 01 Jan 2010
TL;DR: In this article, a square window is opened in the shell after removal of 2−3 ml of albumen to detach the CAM from the shell itself and the underlying CAM vessels are disclosed.
3
Determination of vascularization of B-cell non-Hodgkin's lymphomas with four markers
Angelo Vacca,Domenico Ribatti,Giampietro Gasparini,Massimo Fanelli,M Minischetti,G Ritelli,F Costantino,Monica Iurlaro,Emanuela Bonoldi,F. Dammacco +9 more
TL;DR: This study suggests that angiogenesis and tenascin expression are associated phenomena in B-NHL, and that both increase with the malignancy grade.
3
Exogenous heparin induces an increase in glycosaminoglycans of the chick embryo chorioallantoic membrane: its possible role in the regulation of angiogenic processes.
TL;DR: HE inoculation induced an increase of 3H-glucosamine incorporation into total GAGs in comparison to control CAMs and altered the balance between the GAG classes.
3
•Journal Article
Ultrastructural study of the developing blood capillaries in the pineal gland of the domestic fowl.
TL;DR: The ultrastructure of the pineal gland capillaries in chick embryos of 7, 14 and 19 days of incubation and in three month chicks has been analyzed and shows that vascular primordia are detectable among the Pineal developing vesicles on the 7th incubation day.
3
The Origins of Lymphatic Vessels: An Historical Review
Domenico Ribatti
- 01 Jan 2018
TL;DR: Knowledge of lymphatic development has now been redefined at the molecular level, providing an interesting target for innovative therapies.
3